Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Abstract Full Text (PDF, 432K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JGP Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nelson, M. E. Articles by Lindstrom, J. Search for Related Content PubMed PubMed Citation Articles by Nelson, M. E. Articles by Lindstrom, J. Social Bookmarking                            What's this?

Original Article

Functional Properties of Human Nicotinic Achrs Expressed by Imr-32 Neuroblastoma Cells Resemble Those of 3β4 Achrs Expressed in Permanently Transfected Hek Cells

^a Department of Neuroscience, University of Pennsylvania Medical School, Philadelphia, PA 19104
217 Stemmler Hall, University of Pennsylvania Medical School, Philadelphia, PA 19104-6074.(215) 573-2015

jslkk{at}mail.med.upenn.edu

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
We characterized the functional and molecular properties of nicotinic acetylcholine receptors (AChRs) expressed by IMR-32, a human neuroblastoma cell line, and compared them to human 3 AChRs expressed in stably transfected human embryonic kidney (HEK) cells. IMR-32 cells, like neurons of autonomic ganglia, have been shown to express 3, 5, 7, β2, and β4 AChR subunits. From these subunits, several types of 3 AChRs as well as homomeric 7 AChRs could be formed. However, as we show, the properties of functional AChRs in these cells overwhelmingly reflect 3β4 AChRs. 7 AChR function was not detected, yet we estimate that there are 70% as many surface 7 AChRs in IMR-32 when compared with 3 AChRs. Agonist potencies (EC₅₀ values) followed the rank order of 1,1-dimethyl-4-phenylpiperazinium (DMPP; 16±1 µM) > nicotine (Nic; 48 ± 7 µM) cytisine (Cyt; 57 ± 3 µM) = acetylcholine (ACh; 59 ± 6 µM). All agonists exhibited efficacies of at least 80% relative to ACh. The currents showed strong inward rectification and desensitized at a rate of 3 s^–1 (300 µM ACh; –60 mV). Assays that used mAbs confirmed the predominance of 3- and β4-containing AChRs in IMR-32 cells. Although 18% of total 3 AChRs contained β2 subunits, no β2 subunit was detected on the cell surface. Chronic Nic incubation increased the amount of total, but not surface 3β2 AChRs in IMR-32 cells. Nic incubation and reduced culture temperature increased total and surface AChRs in 3β2 transfected HEK cells. Characterization of various 3 AChRs expressed in HEK cell lines revealed that the functional properties of the 3β4 cell line best matched those found for IMR-32 cells. The rank order of agonist potencies (EC₅₀ values) for this line was DMPP (14 ± 1 µM) = Cyt (18 ± 1 µM) > Nic (56 ± 15 µM > ACh (79 ± 8 µM). The efficacies of both Cyt and DMPP were 80% when compared with ACh and the desensitization rate was 2 s^–1. These data show that even with the potential to express several human nicotinic AChR subtypes, the functional properties of AChRs expressed by IMR-32 are completely attributable to 3β4 AChRs.

Key Words: nicotinic receptor • autonomic • patch clamp

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
3 acetylcholine receptors (AChRs) have been identified as the predominant neuronal AChR in ganglia of the autonomic nervous system (Sargent 1993; McGehee and Role 1995). Most ganglionic neurons express a repertoire of nicotinic subunits that typically includes 3, 5, 7, β2, and β4. Much evidence suggests that the 3 AChR is the main mediator of the nicotinic postsynaptic response in autonomic ganglia (Covernton et al. 1994; Mandelzys et al. 1994; Rust et al. 1994). Knockout mice that lack 3 subunits illustrate the critical role played by these AChRs in the peripheral nervous system. These animals have increased perinatal mortality and exhibit severe physiologic impairment in organs innervated by the autonomic nervous system (Xu et al. 1999a). 7 AChRs are expressed widely in ganglia, also. Selective inhibition of 3 AChRs failed to block synaptic transmission in chick ciliary ganglion showing that 7 AChRs are sufficient to sustain transmission in this preparation (Ullian et al. 1997). Knockout mice lacking 7 AChRs had normal nervous system development (Orr-Urtreger et al. 1997), but exhibited impaired hypotensive reflex tachycardia (Franceschini et al. 2000). Since the loss of 3 function in mice is lethal largely due to autonomic dysfunction, the inability of 7 AChRs to sustain adequate function brings into question its specialized role in the autonomic nervous system.

Knockout mice that lack both β2 and β4 subunits are similar in phenotype to the 3 knockout animals (Xu et al. 1999b). Mice that lacked only the β4 subunit survived but exhibited profound reduction in nicotine (Nic)-induced whole-cell currents in superior cervical ganglion. These animals maintained sufficient autonomic function, presumably, through β2 subunit redundancy or compensation. Mice lacking the β2 subunit had apparently normal organ function and normal whole-cell currents in superior cervical ganglion. Even after these elaborate genetic perturbations, many questions remain regarding nicotinic signaling within the autonomic nervous system. In particular, to what extent does 3β2, 3β4, or 7 AChRs normally contribute to ganglionic transmission, and what other roles do they have? A better understanding of the functional properties of these AChRs as well as how AChR expression might be regulated will help to clarify these issues. IMR-32 cells provide a useful model with which to study the subunit composition of human ganglionic AChRs as they express the characteristic complement of "ganglionic" AChR subunits. Additionally, we have developed a series of cell lines that express 3 AChRs formed from combinations of these ganglionic subunits. We determined and then compared the functional properties of recombinant AChRs with "native" AChRs that are expressed by IMR-32 cells. We use functional and pharmacological profiling to investigate further the subunit composition of human AChRs expressed by IMR-32 cells and support our conclusions with various antibody-based molecular techniques.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Tissue Culture
Transfected human embryonic kidney (HEK) tsA201 cells were maintained in DME medium as described previously (Wang et al. 1998). Cytotoxic selection antibiotics were added to the media to ensure integrity of AChR subunit expression. 0.5 mg/ml Zeocin (Invitrogen) was used for 3 subunit expression, 0.6 mg/ml G-418 (Life Technologies) was used for β2 or β4 subunit selection, and 0.2 mg/ml hygromycin B (Boehringer Mannheim) was used for 5 subunit selection. IMR-32 neuroblastoma cells (Tumilowicz et al. 1970) were obtained from American Tissue Culture Collection and SH-SY5Y neuroblastoma cells (Ross et al. 1983) were provided by June Biedler and Barbara Spengler of Sloan Kettering Institute for Cancer Research. Both were maintained in media consisting of a 1:1 mixture of HAMs F-12 (Sigma-Aldrich) and Eagle's minimum essential medium (Sigma-Aldrich) with penicillin (100 U/ml) and streptomycin (100 µg/ml; Life Technologies) and 10% FBS (Hyclone).

Electrophysiology
At least 2 d before recording, HEK cells were plated onto glass coverslips coated with rat tail collagen (Type 1; Collaborative Biomedical Products), and the IMR-32 cells were plated onto glass coverslips coated with mouse laminin (Collaborative Biomedical Products). Currents were measured by standard patch-clamp techniques (Hamill et al. 1981). Agonist-containing solutions were applied to the cells by gravity fed fused glass tubing that was connected to multiple reservoirs mounted above the recording chamber. The recording solution contained the following (in mM): 150 NaCl, 5 KCl, 1 MgCl₂, 2 CaCl₂, 5 HEPES, and was adjusted to pH 7.3 with NaOH. Electrodes (5–8 M) were formed from borosilicate glass and were filled with a solution containing the following (in mM): 150 cesium gluconate, 10 Cs-EGTA, and 10 HEPES, adjusted to pH 7.2 with CsOH. Cell access resistances were typically 8–15 M and were compensated (40–60%) when peak currents were in excess of 2 nA. Cells transfected with 3β2 or 35β2 AChRs were treated for 12 h with Nic (100 µM) followed by a minimum of 1-h wash with normal media before recording (Wang et al. 1998) or were incubated overnight at 29°C to increase the levels of functional AChRs. Currents were activated and recorded as described previously (Wang et al. 1998). Concentration–response curves were constructed and fitted to the following logistic equation in Origin (Ver. 4.1; Microcal Software, Inc.):

where y is the normalized response amplitude, A₁ is the maximum amplitude asymptote of the fit, A₂ is the minimum asymptote of the fit, x is the concentration of agonist, x₀ is the EC₅₀ value, and p is the steepness of the fitted curve. In some cases, the concentration–response relationship would peak and then decline with increasing concentrations of agonist. In the cases where the decline caused an obviously inferior fit, the reduced amplitude responses at higher concentrations were not included in the fit. Desensitization time constants were determined by fitting exponential equations to the data. Representative traces were constructed by opening data files in Axograph 3.55 (Axon Instruments) and exporting data to Canvas 5.0 (Deneba Software, Inc.).

Single-Channel Analysis
Single-channel currents were recorded and analyzed as described previously (Nelson and Lindstrom 1999). In brief, channel activity was recorded in outside-out configuration patches by isolating the patch in a stream of ACh (1–5 µM). Recordings were performed in ND-96 saline also containing 50 mM dextrose, as used previously to characterize single-channel properties for AChRs expressed by IMR-32 cells (Nelson and Lindstrom 1999). Data were sampled offline at 10 kHz (model Axoscope 2.0; Axon Instruments) and filtered at 3 kHz (model 902; 8-pole Bessel, –3 dB; Frequency Devices, Inc.) for analysis. All single-channel analysis and fitting were performed with pClamp 6.0.3 (Axon Instruments).

Production of mAb 337
mAb 337 (mouse IgG) was developed from a bacterially expressed fusion protein consisting of the large cytoplasmic loop located between the M3 and M4 transmembrane domains of the human β4 subunit (amino acids 305–419) coupled at the NH₂ terminus to bacterial glutathione S-transferase (Wang et al. 1998). Mice were immunized with the fusion protein purified from bacterial inclusion bodies. The animals were boosted four times over several months while titers were monitored by test bleeds against human 3β4 AChRs (from transfected HEK cells) in immunoprecipitation assays. 5 d after a final boost with antigen, the animal with the highest titers was killed. Hybridomas for mAb production were formed by fusion of the animal's splenic lymphocytes with Sp2 myeloma cells according to a procedure adapted from (Lane et al. 1986). Wells containing hybridomas were then screened against human 3β4 AChRs by immunoprecipitation assays and positive wells were cloned. As we show here, in addition to recognizing the β4 subunit in its native confirmation, the antibody also recognizes the denatured subunit as well. Lack of cross-reactivity with human 3, 5, or β2 subunits was established using AChRs extracted from the 35β2 cell line with mAb 337-coated microwells using the procedure described below for radioimmune assays. All animals were handled in accordance with guidelines set forth by the Institutional Animal Care and Use Committee (IACUC) at the University of Pennsylvania under approved protocol on file with that office. IACUC operates under an institutional Animal Welfare Assurance (A3079-01) on file with the Office for Protection from Research Risks at the National Institutes of Health.

Radioimmune Assays (RIAs)
IMR-32 and SH-SY5Y cells were grown as described above until just before confluence in T-175 (175 cm²) tissue culture flasks (model Falcon 3112; Becton Dickinson) then detached with 5 mM EDTA in PBS, pelleted by centrifugation, and used immediately or frozen after removal of media. Fresh or frozen IMR-32 cells were suspended and triturated in a 2% Triton X-100 in buffer A (50 mM Na₂HPO₄-NaH₂PO₄, pH 7.5, 50 mM NaCl, 5 mM EDTA, 5 mM EGTA, 5 mM benzamidine, 15 mM iodoacetamide, and 2 mM phenylmethylsulfonyl fluoride at a 3:1–6:1 ratio (buffer volume/cell volume) and placed on a rotating mixer for 2–3 h at 4°C. Cellular debris was removed by centrifugation and supernatant extract was collected.

For solid phase RIA, AChRs solubilized in Triton were incubated in Immulon 4 microwells (Dynatech Laboratories) coated with mAb 210 (specific for 3 and 5 AChRs; Wang et al. 1996), mAb 295 (specific for β2 AChRs; Whiting and Lindstrom 1988), or mAb 337 (specific for β4 AChRs) overnight at 4°C. The labeling of bound AChRs was carried out by including a supersaturating concentration of 10 nM [³H]epibatidine during the incubation in the wells. Unbound material was removed from wells by washing three times with ice-cold 0.5% Triton in PBS. The remaining contents of the wells were stripped with 75 µl of 2.5% SDS containing 5% β-mercaptoethanol and then transferred to liquid scintillation tubes containing 3 ml of Optiphase "Hisafe" 3 scintillation fluid (Fisher Scientific). The amount of bound [³H]epibatidine was determined by liquid scintillation counting for 5 min using a liquid scintillation counter (model Wallac 1410; Perkin-Elmer Wallac). Background was determined using wells coated with BSA or goat anti–rat IgG (GART).

To measure the amount of 3-containing AChRs that could be labeled in intact cells by [³H]epibatidine, IMR-32 cells were plated in 35-mm tissue culture dishes and grown until confluent. At this time, the media was replaced with 0.5 ml of media that contained 2 nM [³H]epibatidine and returned to the tissue culture incubator. For background determinations, 300 µM Nic was added 45 min before [³H]epibatidine. After 2 h at 37°C, the medium was then removed and the cells quickly rinsed with PBS. The cells were removed from the dishes by trituration with 0.5 ml buffer A, and then lysed with an ultrasonic cell disrupter (model Sonifier 200; Branson Ultrasonics Corp.). Membrane fragments were collected on glass fiber filters (model GF/F; Whatman; 25 mm, treated with 0.3% polyethylenimine) followed by four rapid 1-ml washes with ice cold PBS. Filters were then transferred to scintillation tubes for counting of retained [³H]epibatidine.

For isolation and measurement of 7-containing AChRs, microwells were coated with a combination of mAbs 306 and 319 that recognizes human 7 subunits (Peng et al. 1994). Cell extracts were prepared as described above and aliquots were incubated in mAb-coated wells overnight at 4°C with ¹²⁵I--BGT (20 nM; 0.48 Ci/µmol). For background determinations, unlabeled -BGT (200 nM) was included in the incubation 1 h before addition of ¹²⁵I--BGT. After overnight incubation, unbound material was removed as described above and the amount of bound ¹²⁵I--BGT was determined by gamma counting.

Surface AChR Labeling
To measure surface AChRs, cells were collected from tissue culture flasks and gently pelleted by centrifugation followed by a wash in normal culture medium containing 10% FBS. Cells were resuspended in tissue culture medium and aliquoted (500 µl) into microcentrifuge tubes. Surface 3-containing AChRs were labeled by incubation (2–4 h) with ¹²⁵I-mAb 210 (4 nM; 0.46 Ci/µmol) and surface β2-containing AChRs were labeled with ¹²⁵I-mAb 295 (4–6 nM; 0.69 Ci/µmol). Background determinations were made in parallel by including at least 50-fold excess unlabeled mAb in a 1 h preincubation to block specific sites. Incubations were carried out at 37°C with constant mixing. After incubation, cells were diluted with an equal volume of tissue culture media, pelleted, and then washed twice more with clean media. Amount of bound ¹²⁵I-mAb was then determined by gamma counting.

Western Blotting
Triton X-100 extraction of AChRs from IMR-32 and SH-SY5Y neuroblastoma cells were performed as described above. The extracts were incubated overnight at 4°C with mAb-coupled agarose to select and concentrate AChRs. AChRs were isolated using activated CH Sepharose 4B resin (Amersham Pharmacia Biotech) coupled with mAb 210 for 3 AChRs, coupled with mAb 295 for β2 AChRs, or coupled with mAb 337 for β4 AChRs (all at 2 mg mAb/ml of resin). After incubation, bound AChRs were eluted using 3% SDS sample buffer without reducing agents. The samples were loaded on 12% polyacrylamide gels containing SDS and electrophoresed. Transfer of the proteins was done in a semi-dry electroblotting chamber (Semi-Phor; Hoefer Scientific Instruments) to Trans-Blot^® medium PVDF membrane (Bio-Rad). The blot membranes were then quenched for 1 h at room temperature with 5% dried milk in PBS containing 0.5% Tween 20 and 10 mM NaN₃ (PBS/Tween) with constant agitation. Antisera against 3 or β2 subunits (Kuryatov et al. 2000) were then added at 1:200 dilution and incubated overnight at 4°C. After three washes with PBS/Tween, labeling was done by the addition of ¹²⁵I-GART antibodies (2 nM, 0.81 Ci/µmol) for 3 h at room temperature, followed by a brief rinse and three washes (10 min each) with PBS/Tween. ¹²⁵I-mAb 337 (2 nM, 0.83 Ci/µmol) was used to identify the β4 subunit in which case the primary labeling was followed by the wash steps with PBS/Tween. Autoradiography was performed at –80°C with exposures between 10 min and overnight using Kodak Biomax^® MS film and intensifying screen.

Immunofluorescence with Confocal Microscopy
IMR-32 or permanently transfected cells were plated on either laminin-coated or collagen-coated glass coverslips, respectively, and fixed with 10% formalin/PBS for 1 h at room temperature for labeling with fluorescent antibody to track the presence of AChR subunit proteins. Fixed cells were then washed three times with PBS to remove fixative. Attachment of fluorophores to primary antibodies was done using a kit (Molecular Probes) to attach either Alexa fluor 488 or 594 to the antibodies. Primary labeling with unlabeled antibody was performed overnight at 4°C in PBS containing antibody with 5% goat serum. Secondary labeling was carried out after washing three times with PBS to remove the unbound primary antibody, followed by Alexa fluor 594-labeled GART (Molecular Probes) for mAb 295 or Alexa fluor 568-labeled goat anti–mouse (GAM) IgG (Molecular Probes) for mAb 337. Secondary antibodies were used at final concentrations of 4 µg/ml for GART or 3 µg/ml for GAM, and were applied for 3–4 h at room temperature in the presence of 5% goat serum. After washing three times with PBS, primary labeled mAb 210 (Alexa fluor 488) was applied overnight at 4°C at a final concentration of 5 µg/ml in the presence of 5% normal rat serum. To access intracellular AChR subunits, cells were permeabilized with 0.5% Triton X-100 for 1 h at room temperature before labeling with antibodies. To-Pro 3 iodide (Molecular Probes) was included as a nuclear counterstain at 0.5–1 µM for 20–60 min. Coverslips with labeled cells were rinsed twice with PBS and once with deionized water, then mounted on slides using Pro-Long antifade (Molecular Probes), dried, and stored at 4°C until viewed. Images of labeled cells were then acquired using a Leica TCS 4 D laser scanning confocal microscope.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Pharmacological Properties of Functional AChRs in IMR-32 Cells
Rapid application of nicotinic agonists to patch-clamped IMR-32 cells evoked responses ranging up to several hundred picoamps when clamped at –60 mV. An example of a concentration/response family of currents from a cell is shown in Fig. 1A using Cyt. The concentration/response relationships are shown for ACh, Nic, DMPP, and Cyt along with the curve fits used to determine the EC₅₀ values (Fig. 1 B). The rank order of potency was DMPP > Nic Cyt = ACh. This rank order provided a profile for functional native AChR(s) present in IMR-32 cells for comparison with agonist profiles for AChRs of defined composition expressed in transfected cells as described below.

View larger version (27K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Functional and pharmacological properties of AChRs expressed by the human neuroblastoma cell line IMR-32. (A) A family of currents recorded in response to increasing concentrations of Cyt for a cell clamped at –60 mV. In the inset, the scaled response of this cell to a maximally effective concentration of Cyt (300 µM) is shown relative to the response to ACh (300 µM) which was chosen to define agonist efficacy. (B). The full concentration/response relationships are shown for ACh (), Nic (•), Cyt (), and DMPP (). With the exception of DMPP, all agonists had similar potencies. The EC50 values were 66 ± 5 µM for ACh, 48 ± 8 µM for Nic, 57 ± 3 µM for Cyt, and 16 ± 1 µM for DMPP. The relatively high efficacy of Cyt and the relatively high potency of DMPP were the most distinguishing pharmacological properties found for the IMR-32 AChR response. (C). The current/voltage relationship for IMR-32 cells recorded in response to application of 100 µM ACh. The currents were no longer inward at 0 mV, which was consistent with a nonselective cation channel. The currents exhibited strong inward rectification, but when depolarized beyond +60 mV, outward currents were observed. (D). Representative recording and exponential fit of the current decay for IMR-32 cells.

Functional Properties of IMR-32 AChRs
The current-voltage relationship for ACh-activated currents from IMR-32 cells were studied between –120 and +80 mV (Fig. 1 C). The currents approached reversal when the holding potential was between –10 and 0 mV, which is expected for nonselective cation channels under these recording conditions. Additionally, strong inward rectification was found at positive holding potentials until +60 mV, where some reversal was observed.

Desensitization of currents recorded from IMR-32 cells was usually best described by a single exponential function which could be fit with a time constant of decay of = 368 ± 94 ms (n = 8) (Fig. 1 D). In some cases, the desensitization was fit best by a double exponential function with time constants of 73 ± 27 ms and 550 ± 136 ms (n = 2). In addition to desensitization during the application of agonist, the peak amplitude of the currents decreased slightly over the course of a full concentration/response experiment. This "rundown" was not prevented by inclusion of various agents in the recording electrode such as ATP, creatine phosphokinase, phosphocreatine, and magnesium, or various combinations of these substances. Additionally, using a recording solution that was based on CsCl also did not prevent the rundown (unpublished data).

Effects of Nicotinic Antagonists on IMR-32 Currents
Responses to 100 µM ACh were antagonized by coapplication of the antagonists d-tubocurare, mecamylamine, and hexamethonium with IC₅₀ values of 0.4 ± 0.2, 3.2 ± 0.6, and 8.5 ± 3.0 µM, respectively (Fig. 2 A). The reversible 7 selective antagonist, methyllycaconitine (MLA), had no effect on Nic-activated (300 µM) currents when applied at 20 nM with a 10 min preincubation (Fig. 2 B). This concentration of MLA (20 nM) was almost three orders of magnitude higher than the IC₅₀ reported for homomeric 7 AChRs (Palma et al. 1996) or 7 containing AChRs in rat hippocampal neurons (Alkondon et al. 1992). The lack of antagonism by MLA was consistent with the fact that the currents lacked the rapid desensitization that is a hallmark property of 7 AChRs. To validate the ability of our application system to activate 7 AChRs efficiently before they desensitized, we recorded the rapidly desensitizing Nic-activated currents that have been attributed to 7 AChRs from rat hippocampal neurons (unpublished data). Thus, it was concluded that any contribution of 7 AChRs to macroscopic currents from IMR-32 cells was negligible.

View larger version (13K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Antagonist sensitivity of the AChR currents activated in IMR-32 cells. (A) The concentration response relationship is shown for d-tubocurare (d-TC; ), mecamylamine (Mec; ), and hexamethonium (C-6; •) on IMR-32 cells with IC50 values of 0.4 ± 0.2, 3.2 ± 0.6, and 8.5 ± 3.0 µM, respectively. All drugs were coapplied with 100 µM ACh at a holding potential of –60 mV. The peak amplitudes of the resulting currents were then plotted against concentration of the antagonist after normalizing to the peak amplitude of the current recorded in the absence of any antagonist. All three drugs completely blocked the currents at higher concentrations. (B) Representative currents are shown for testing the sensitivity of IMR-32 AChR currents to the reversible 7 selective antagonist MLA (20 nM). No inhibition was observed, which was consistent with the idea that the macroscopic current recorded in the cells reflects predominately the activity of 3 AChRs.

Agonist Potencies and Efficacies in Permanently Transfected 3 AChR Cell Lines

View larger version (25K): [in this window] [in a new window] [Download PPT slide]   Figure 3 Efficacy of Cyt on 3 AChRs expressed by permanently transfected HEK cells is determined by whether the AChR contains a β2 or β4 subunit. Representative currents are shown for permanently transfected cell lines that express 3β2, 3β25, 3β4, and 3β45 AChRs. For each cell, a pair of currents are superimposed that reflect current activated by a near saturating (300 µM) concentration of ACh and a maximally effective concentration (300 µM) of Cyt. Clearly, the efficacy of Cyt relative to ACh in the cell lines that express the β2 subunit is far lower (5% or less) than that found for the cell lines that express the β4 subunit (80% or more).

View larger version (28K): [in this window] [in a new window] [Download PPT slide]   Figure 4 Concentration-response relationships for nicotinic agonists on 3 AChRs in permanently transfected HEK cells establish potency and efficacy profiles that allow for distinguishing β2 and β4 containing AChRs. Each panel depicts the concentration-response relationship for the indicated permanently transfected 3 cell line. The symbols reflect correspond to different agonists as follows: ACh (), Nic (•), Cyt (), and DMPP (). The EC50 values are shown in Table . Each point in the figure represents the peak amplitude of the current evoked by that concentration of agonist normalized to the peak amplitude of the current evoked by 300 µM ACh in the same cell. The cells were clamped at –60 mV for 3β2 and 35β2 and at –30 mV for 3β4 and 35β4 cell lines. β4 AChRs were more sensitive to activation by ACh, whereas β2 AChRs were slightly more sensitive to activation by DMPP. Cyt had virtually no efficacy in activating β2 AChRs, whereas it had >50% efficacy on β4 AChRs. DMPP exhibited efficacy that was equal to, or higher than ACh on β2 AChRs, but it was <50% efficacious on β4 AChRs. Nic was poor in distinguishing between β2 and β4 AChRs. The data for ACh and Nic are taken from Wang et al. 1998.

Reduced Temperature Increases Functional 3β2 AChRs
When incubated at reduced temperature (29°C) overnight, 3β2 cells increased their amount of functional AChRs as judged by the gain of responsiveness to agonist, much like when the cells were incubated in Nic overnight (Wang et al. 1998). The temperature-induced AChR increase was similar to a recent report for 4β2 AChRs expressed in HEK cells (Cooper et al. 1999). Since our functional studies with 3β2 or 35β2 AChRs required exposure to Nic before recording, we were unable to determine if the agonist exposure itself altered functionality when compared with naive AChRs. However, the temperature-induced increase in AChRs allowed us to characterize 3β2 AChRs without prior exposure to Nic (Fig. 5 A). The EC₅₀ value for cells incubated at 29°C was 202 ± 14 µM, which compares well to the EC₅₀ of 209 ± 26 µM for cells incubated in Nic (Fig. 5 B). Since the functional properties were the same regardless of treatment, it seems unlikely that Nic-treated 3β2 AChRs have properties that differ from 3β2 AChRs that have not been Nic-treated. Previous studies with 3β2 AChRs expressed in Xenopus oocytes showed that this Nic treatment did not alter the functional properties of the AChR (Wang et al. 1998). By contrast with the Nic-induced increase in surface 3β2 AChRs in the transfected cell line that was reflected by the appearance of substantial electrophysiological responses, overnight incubation of IMR-32 cells in Nic did not increase the amount of 3β2 AChRs on the surface of these cells (see last paragraph of Subunit Content of AChRs...) or alter their functional properties in a way that might reflect an increase in surface 3β2 AChRs (Fig. 5 C, compare with Fig. 1 A, inset). Similar results were found for IMR-32 cells incubated at 29°C (unpublished data).

View larger version (36K): [in this window] [in a new window] [Download PPT slide]   Figure 5 Culturing the 3β2 AChR cell line at 29°C increases the population of functional AChRs similar to overnight incubation in Nic. (A) A family of representative currents is shown for the concentration-response relationship for 3β2 cells that were placed at 29°C for at least 6 h and as long as 48 h. For comparison, currents recorded from cells that were incubated in Nic (100 µM) overnight are also shown (Wang et al. 1998). (B) The sensitivity to activation by ACh for the cells grown at reduced temperature were identical to those that had been incubated overnight in 100 µM Nic. The full concentration/response for both conditions is also shown. Responses were normalized to the response peak measured for 300 µM ACh for each cell. The EC50 for each condition was 202 ± 14 µM for cells grown at 29°C () and was 209 ± 26 µM for cells incubated overnight in Nic (). (C) Representative currents are shown for IMR-32 cells that were incubated overnight in Nic (100 µM). The responses to 300 µM ACh and 300 µM Cyt are nearly identical to currents recorded from naive IMR-32 cells (Fig. 1 A, inset).

Transfection of 3β4 and 3β2 Cell Lines with the 5 Subunit Had Little Effect on the Functional or Pharmacological Properties when Compared with the Parent Cell Line

Agonist Sensitivity and Efficacy Profiles for 3 Cell Lines and IMR-32 Cells
We used the pharmacological data for AChRs in transfected cells to establish prediction criteria for the presence of either β2 or β4 subunits in native human 3 AChRs that are expressed by IMR-32 cells. 3 AChRs that are relatively insensitive to activation by ACh (i.e., have EC₅₀ values greater than 100 µM) and show full efficacy to activation by DMPP are likely to possess β2 subunits. AChRs where Cyt has significant efficacy and DMPP has less than full efficacy are likely to contain β4 subunits. The agonist potency profiles found for the 3β4 and 35β4 cell lines most closely resemble that found for IMR-32 cells (Fig. 6 A). Since the 35β4 cell line incorporates 5 subunit, the best match is between IMR-32 and the 3β4 cell line.

View larger version (43K): [in this window] [in a new window] [Download PPT slide]   Figure 6 Agonist potency and efficacy profiles for HEK 3 cell lines and IMR-32 cells. (A) Bar graph depicting the EC50 values from Fig. 4 for ACh, Nic, Cyt, and DMPP on the HEK transfected cell lines and IMR-32 cells. The potency profile for IMR-32 cells best matches the profiles for the 3β4 and the 3β45 cell lines. The biggest discrepancy was seen for the potency of Cyt, which was higher on the β4 containing transfected cell lines than on IMR-32 cells, but the potencies of the other three agonists matched well. (B) Bar graph depicting the efficacies of the four agonists on the HEK transfected cell lines and IMR-32 cells. The efficacies of Cyt and DMPP serve as good predictors of the β subunit identity in unknown AChRs. Thus, for IMR-32 AChRs, the efficacy of both Cyt and DMPP along with the agonist potency profiles lead us to conclude that the predominant AChR in these cells is 3β4.

Effect of Holding Potential on Agonist Properties for 3β4 AChRs in HEK Cells
For ACh and Nic, the EC₅₀ values were greater at –30 mV (79 ± 8 µM and 56 ± 10 µM, respectively) than at –60 mV (43 ± 10 µM and 35 ± 6 µM, respectively) whereas for DMPP the EC₅₀ was little changed (15 ± 1 µM at –30 mV and 14 ± 1 µM at –60 mV). Reducing the holding potential also altered the efficacy of Nic and DMPP relative to ACh. The efficacy of Nic peaked between 300 µM and 1 mM at –30 mV, whereas the peak occurred at 100 µM at –60 mV. For DMPP, the efficacy relative to ACh increased from 50 to 65% by depolarizing from –60 to –30 mV. Thus, the effect of holding potential on the concentration-response relationship probably represents the impact of voltage on channel blockade by these agonists, but could also reflect voltage-dependent gating transitions.

All AChRs Exhibited Rectification Regardless of Subunit Composition
Strong inward rectification is a hallmark property of neuronal nicotinic AChRs. It was attributed to intracellular magnesium for -BGT–sensitive currents in rat hippocampal neurons (Alkondon and Albuquerque 1994). The rectification was removed by mutations in amino acids that flank the channel forming region of 3β4 and 4β2 AChRs (Haghighi and Cooper 1998). Channel block by internal polyamines was also reduced by these mutations (Haghighi and Cooper 1998; Haghighi and Cooper 2000). All of the HEK 3 AChR cell lines exhibited inward rectification (Fig. 7). The current-voltage relations approach reversal between 0 and +5 mV, but failed to become outward at positive holding potentials up to +60 mV. Recordings at +100 mV with the 35β2 cell line had small outward currents that were 15% of the currents recorded at –100 mV (unpublished data). If polyamines caused the rectification, its persistence throughout 45–75-min recordings indicated that the large dilution by electrode solution was insufficient to relieve the channel block. Magnesium or another ion in the electrode solution could also be responsible for the rectification.

View larger version (27K): [in this window] [in a new window] [Download PPT slide]   Figure 7 Current-voltage relations for 3 AChRs expressed by permanently transfected HEK cells exhibit the strong inward rectification that is characteristic of neuronal nicotinic AChRs. For the four 3 AChR cells lines, currents were activated by 100 µM ACh at fixed holding potentials spanning –80 to +60 mV. The peak amplitudes of the currents are shown plotted against holding potential after normalizing to the amplitude of the peak current measured at –80 mV. In all cases the current ceased to be inward at a holding potential between 0 and +5 mV consistent with a nonselective cation channel. No outward currents were detected at holding potentials up to +60 mV.

View larger version (25K): [in this window] [in a new window] [Download PPT slide]   Figure 8 3 AChRs containing the β2 subunit desensitize faster than those that contain the β4 subunit. Currents evoked by ACh (300 µM) in each 3 cell line are shown along with the fit of the current decay to either a single or double exponential function. Both 3β2 and 35β2 AChRs exhibited desensitization with a very rapid component having time constants of <100 ms. Some of the 3β2 cell currents could be fit by double exponential functions (5 out of 7) with the faster component matching the cells which had only a single exponential decay as well as a slower component that was several hundred milliseconds. Some of the 35β2 AChR currents (7 out of 12) had a small amplitude slower component. Both the 3β4 and the 35β4 AChRs had currents that desensitized much slower than the β2-containing AChRs and were always best fit by single exponential functions which had time constants of decay of 500 ms. All desensitization time constants were determined for currents that were recorded at –60 mV.

Single-channel Properties of 3β4 AChRs Expressed in HEK Cells Closely Match Those of AChRs Expressed by IMR-32

View larger version (16K): [in this window] [in a new window] [Download PPT slide]   Figure 9 The single-channel properties for 3β4 AChRs from transfected HEK cells are nearly identical to those for 3β4 AChRs expressed in Xenopus oocytes and for IMR-32. Representative recordings of the single-channel currents for 3β4 AChRs expressed in permanently transfected HEK cells are shown along with representative event amplitude and dwell time distributions. Superimposed on the event histograms are fits to either a double Gaussian function for the amplitude distribution or a double exponential function for the open time distribution. The recordings were made in the outside-out patch configuration using ACh (5 µM) as agonist at -80 mV. Mean channel open times were determined as described in MATERIALS AND METHODS. The single-channel amplitudes and open times were nearly identical to those for oocyte-expressed AChRs and for IMR-32 AChRs recorded under the same conditions (Nelson and Lindstrom 1999; see preceding page).

View larger version (29K): [in this window] [in a new window] [Download PPT slide]   Figure 10 Incubation in Nic increases the amount of 3β2 AChRs in IMR-32 and SH-SY5Y cells, but not 3β4 AChRs. The bar graph represents the relative amounts of [3H]epibatidine binding to AChRs immunoisolated on mAb-coated microwells from Triton-X100 extracts of either IMR-32 or SH-SY5Y cells in the presence and absence of Nic (100 µM) overnight. mAb 210 binds 3 and 5 AChRs, mAb 295 binds β2 AChRs, and mAb 337 binds β4 AChRs. For both cell lines, Nic caused an increase in binding to AChRs isolated on 210-coated wells which was the same in magnitude as the amount of increase in binding to AChRs isolated on mAb 295-coated wells. AChRs isolated on mAb 337-coated wells were not altered significantly by Nic. For IMR-32 (untreated), mAb 210 isolated AChRs bound 12 fmol of [3H]epibatidine, which corresponds to roughly 1,800 AChRs per cell when assuming two binding sites per AChR, whereas for SH-SY5Y, mAb 210 isolated AChRs bound 3 fmol of [3H]epibatidine corresponding to 600 AChRs per cell.

Immunofluorescence and Confocal Microscope
Confocal microscopy was used to visualize the distribution of 3 AChRs in IMR-32 neuroblastoma cells and the 3β2 or the 3β4 transfected cells. For the transfected cells, intense, clustered labeling was observed with antibody directed against the 3 subunit. The labeling of 3 largely overlapped with the labeling observed with antibody directed against the β4 subunit in the 3β4 cells and the β2 subunit in the 3β2 cells (Fig. 11). In the case of IMR-32 cells, the labeling of 3 subunit was also extensive and appeared in clusters that overlapped with the labeling observed for antibody directed at the β4 subunit (Fig. 11). Since mAb 337 (to β4) targets a cytoplasmic epitope, all images are shown for permeabilized cells. The clustered appearance of the 3 label was also observed on nonpermeabilized cells, indicating that surface AChRs were expressed in concentrated densities (unpublished data). The 3β4 cells seem to have the largest size clusters, which probably reflects the fact that these cells express the greatest levels of AChR (Wang et al. 1998).

View larger version (40K): [in this window] [in a new window] [Download PPT slide]   Figure 11 Confocal microscopy of 3 AChRs expressed by IMR-32 neuroblastoma cells and HEK cells transfected with 3β4 and 3β2 AChRs. Cells were plated, fixed, permeabilized, and labeled as described in MATERIALS AND METHODS. For each cell type, green reflects labeling of 3 subunits by Alexa 488-labeled mAb 210. For IMR-32 cells and 3β4 cells, red reflects secondary labeling by Alexa 568-labeled GAM antibody against mAb 337 which bound β4 subunits. For 3β2 cells, red reflects secondary labeling by Alexa 594-labeled GART antibody against mAb 295 which bound β2 subunits. Yellow is a result of overlap in the labeling of colocalized subunits. For all cells, ToPro-3 iodide (blue) was included as a nuclear counterstain. The scale bars in the 3β4 panel represent 1, 2, 5, and 10 µm, respectively.

View larger version (45K): [in this window] [in a new window] [Download PPT slide]   Figure 12 Western blots of neuroblastoma AChRs compared with AChRs expressed in permanently transfected HEK cells. AChRs in Triton X-100 extracts were immunoisolated on mAb-coated resin. 3-containing AChRs were isolated by mAb 210. β2-containing AChRs were isolated by mAb 295. β4-containing AChRs were isolated by mAb 337. Proteins were separated by electrophoresis in SDS on a 12% polyacrylamide gel. 3 subunit protein was bound with rat antisera raised against the 3 subunit and then labeled with 125I-GART. β4 subunit protein was labeled directly with 125I-mAb 337.

Presence of a-BGT Binding AChRs in IMR-32 Cells That Do Not Contain 3, 5, or β2 Subunits

It is possible that IMR-32 cells express heteromeric 7-containing AChRs with slower kinetics that are insensitive to inhibition by MLA. To detect such an AChR we used microwells coated with either mAb 210 (to 3 or 5 subunits) or mAb 295 (to β2 subunits) and tested for -BGT binding. For AChRs isolated with either mAb, no ¹²⁵I--BGT binding was detected (Fig. 13), but wells coated with 7-selective mAbs 306 and 319 bound 40 ± 4 fmol of ¹²⁵I--BGT from these same extracts. We conclude that in IMR-32 cells, no -BGT binding AChRs are formed by the coassembly of 3, 5, or β2 subunits with the 7 AChR subunit.

View larger version (48K): [in this window] [in a new window] [Download PPT slide]   Figure 13 Only IMR-32 AChRs immunoisolated with mAbs to 7 AChR subunit bind -BGT. The bar graph depicts the relative amounts of 125I--BGT binding that occurred on mAb-coated microwells after isolation of IMR-32 AChRs solubilized in Triton X-100. Microwells coated with a combination of mAbs 306 and 319 which both recognize 7 subunits bound 35-45 fmol of 125I--BGT, whereas microwells coated with mAbs 210 (which recognizes 3 or 5 subunits) or 295 (which recognizes β2 subunits) exhibited virtually no binding above background for the same AChR extracts. Extracts from IMR-32 cells that had been treated overnight with Nic (100 µM) bound slightly less 125I--BGT than cells that were not treated with Nic when bound on wells coated with mAbs 306/319.

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
IMR-32 cells were derived from an abdominal tumor (Tumilowicz et al. 1970) and express nicotinic AChR subunits that are typical of ganglionic neurons: 3, 5, 7, β2, and β4 (Gotti et al. 1997). Although several AChR subtypes could be formed from these subunits, our data show that the functional properties of IMR-32 AChRs resemble those of 3β4 AChRs expressed in transfected HEK cells. No evidence was found for 3β2 or 7 AChR-mediated currents from IMR-32 cells. 3β2 AChRs represented a small percentage of total IMR-32 3-AChRs and were absent from the cell surface. However, the amount of surface 7 AChRs appeared to be similar to the amount of surface 3 AChRs. The absence of function for 3β2 or 7 AChRs could result from differential downregulation of these AChRs in the present developmental state of these cells. Incubation in Nic or culturing at reduced temperature increased the amount of 3β2 AChRs in IMR-32 cells, but not on their surface, in spite of the dramatic increase in surface expression observed for 3β2 AChRs expressed in HEK cells after these treatments.

Transgenic deletions in mice of the 3, β2, and β4 subunits provided evidence that each of the subunits can contribute to AChRs that mediate autonomic transmission (Xu et al. 1999a,Xu et al. 1999b). However, the overlap in expression of β subunits and possible compensatory upregulation of other subunits in knockout animals prevents isolation of the specialized roles that particular 3 AChR subtypes might play. Also, the morbidity induced by 3 deletion shows the inability of 7 AChRs alone to sustain adequate autonomic synaptic function and provides indirect evidence for distinct roles played by these AChRs. A better understanding of functional differences among AChR subtypes is key to clarifying their roles played in the physiology of the autonomic nervous system.

Comparisons between the Functional and Pharmacological Properties of 3 AChRs Expressed by Permanently Transfected HEK Cells and IMR-32 Cells
The rank order of agonist potencies on IMR-32 cells (DMPP > Nic Cyt = ACh) was similar to reports for ganglionic preparations from both rat and chicken (Sargent 1993; McGehee and Role 1995). All of the agonists on IMR-32 cells had nearly full efficacies (80%). Currents from IMR-32 cells exhibited strong inward rectification and a relatively slow rate of desensitization. They were insensitive to 7-selective concentrations of methyllycaconitine, the potent reversible competitive antagonist of 7-containing AChRs.

In transfected cells, the rank order of potencies for 3β4 AChRs was DMPP = Cyt > Nic > ACh, which was similar to the rank order for IMR-32 AChRs. Moreover, with the exception of Cyt, the EC₅₀ values found for agonists on 3β4 AChRs were nearly identical to those found for IMR-32 AChRs (Table ). Although the rank order of potencies for 35β4 cells was also similar to IMR-32 cells, both of these cell lines express few 5-containing AChRs (Wang et al. 1998; Nelson and Lindstrom 1999). Cyt clearly differentiates between β2- and β4-containing AChRs (Papke and Heinemann 1994) with 70% efficacy on both 3β4 cells and IMR-32 cells, but 5% or less on 3β2 or 35β2 transfected cells. Desensitization kinetics were similar between 3β4 AChRs and IMR-32 AChRs, both of which were much slower than the decay kinetics of 3β2 AChRs. Finally, the single-channel open times and channel amplitudes for the HEK-expressed 3β4 AChRs were nearly identical to those recorded from oocytes and very similar to those recorded from IMR-32 cells (Nelson and Lindstrom 1999).

These functional data failed to eliminate the possibility that IMR-32 AChRs consist of 3 and β4 subunits coassembled with β2 and/or 5 subunits since all possible subunit combinations were not tested in permanently transfected cell lines. It is conceivable, for example, that coassembly with β4 might mask the presence of β2 subunits in IMR-32 AChRs. However, the present and past molecular evidence help to dispel this concern. Here, we have shown that mAb 295 (specific for the β2 subunit) isolated <20% as many AChRs as mAb 210 (specific for 3 AChRs) from IMR-32 cell detergent extracts and it labeled no AChRs on the cell surface (see last paragraph of Subunit Content of AChRs... and next section). Previously, we showed that the amount of 5-containing AChRs in IMR-32 cells is 5% when compared with the amount of 3-containing AChRs (Nelson and Lindstrom 1999). These data taken together support the conclusion from our functional studies that the main AChR expressed by IMR-32 cells is composed of 3 and β4 subunits. Furthermore, the similarities in functional properties between IMR-32 AChRs and 3β4 AChRs expressed in HEK cells illustrate two important points: (1) the population of functional IMR-32 AChRs is homogenous, and (2) the expression environment does not appear to modify the functional properties of 3β4 AChRs.

Effects of Chronic Nic Exposure on AChRs of IMR-32 and SH-SY5Y
Previous studies demonstrated that Nic (micromolar range) incubation increased total 3 AChRs while the number of surface AChRs was unchanged in SH-SY5Y cells (Peng et al. 1997) or increased in HEK cells expressing 3β2 AChRs (Wang et al. 1998). Nic upregulation appears to be selective for human 3β2 AChRs since no effect was seen on human 3β4 AChRs (Wang et al. 1998). Nic concentrations required to upregulate 3β2 AChRs are substantially greater than the concentrations that are typically achieved in serum of cigarette smokers (Benowitz et al. 1990). Upregulation of 3β2 AChRs by high concentrations of Nic reveals a mode of modulation that could be common among AChRs that contain β2 subunits. The upregulation has been attributed to promoting AChR assembly coupled with reduced AChR turnover (Peng et al. 1997; Wang et al. 1998). Competitive antagonists did not block upregulation of 3β2 AChRs in HEK cells, but they caused low levels of upregulation in the absence of Nic (Wang et al. 1998). Mecamylamine, a noncompetitive antagonist, blocked upregulation and had no effect on amount of AChR by itself. Clearly, a drug-induced change in AChR conformation must occur, but the actual signaling pathway remains unclear. Nic increased 3-containing AChRs in IMR-32 cells to a lesser extent than those in SY-SY5Y cells. The difference in the extent of upregulation is consistent with the relative abundance of the β2 subunit in each of the neuroblastoma cells. In fact, β2-containing AChRs accounted for the majority of the AChR increase caused by Nic, whereas β4-containing AChRs were unaffected in both IMR-32 and SH-SY5Y cells.

No significant surface β2 AChRs were detected by antibody in IMR-32 cells, with, or without, Nic treatment. Also, Nic caused no change in the amount of antibody labeling of surface 3 AChRs. For SH-SY5Y, incubation in Nic caused no significant change in the number of 3- or β2-containing surface AChRs. Because the total number of AChRs expressed by these cells increased, whereas the number of surface AChRs was unchanged after incubation in Nic, AChRs must accumulate intracellularly as suggested previously (Peng et al. 1997).

Why might 3β2 and 3β4 AChRs within ganglionic neurons have distinct posttranslational regulatory mechanisms? IMR-32 and SH-SY5Y cells represent noninnervated human ganglionic neurons in a suspended state of maturity. The fact that they express different proportions of 3β2 and 3β4 AChRs and that 3β2 levels can be selectively increased by exposure to Nic or by reducing culture temperature shows that mechanisms exist that specifically regulate expression of 3β2 AChRs in ganglia at certain times of development, stress, or activity. It is interesting that our 3β2 cell line increases surface AChRs by these treatments, whereas the neuroblastoma cell lines do not. This could mean that other factors such as chaperone proteins or cytoskeletal-associated proteins (analogous to rapsyn for muscle AChRs [Bloch and Froehner 1987], gephyrin for glycine receptors [Betz et al. 1991], or GABA receptor–associated protein [Wang et al. 1999]) regulate surface expression, and that the presence of these components differs between HEK and the neuroblastoma cells. From the knockout mice studies, it seems that ganglionic AChRs composed of either β2 or β4 subunits are at least minimally sufficient to maintain autonomic function. Although the simplest conclusion would be that both of these AChRs mediate synaptic transmission, it is more likely a reflection of the limitations of nonconditional knockouts where compensatory substitution of one subunit for the missing subunit occurs. The significance of the particular β subunit that is expressed could play a role in subcellular signaling that controls synaptic establishment, maintenance, or control of expression of yet another target protein. Specific regulation of 3β2 AChR expression could be used to achieve these different goals. Comparisons between 3β2 and 3β4 cell lines reveal clear functional differences between these AChRs. 3β2 AChRs are less sensitive to activation and desensitize much more quickly than 3β4 AChRs. Additionally, 3 AChRs containing the β2 subunit have higher Ca²⁺ permeability than 3 AChRs containing the β4 subunit (Gerzanich et al. 1998). It is possible that regulation of β subunit expression is analogous to the developmental regulation of and subunits in fetal and adult muscle AChR, respectively. AChRs having the subunit exhibit smaller conductance, longer gating periods, and are not confined to the neuromuscular junction when compared with -containing AChRs (Hall and Sanes 1993). This difference in functional properties reflects differing needs of the muscle fiber at different stages of development. Although the conductances of the 3β2 and 3β4 AChRs are not significantly different, the gating kinetics differ significantly with the β4-containing AChRs exhibiting much longer open and burst times than 3β2 AChRs (Nelson and Lindstrom 1999). Their unique gating properties, along with their differential regulation, allow these 3 AChR subtypes to play specialized roles in ganglionic neurons.

Both neuroblastoma cell lines produce low amounts of 5-containing AChRs. For IMR-32 cells, 5% of 3 AChRs contained the 5 subunit. Such low levels would be insufficient to alter macroscopic currents. However, the same reasoning that was applied to regulated expression of β2-containing AChRs in ganglia could also be applied to 5-containing AChRs. Considering the impact of the 5 subunit on 3-AChR gating, conductance, and permeability (Gerzanich et al. 1998; Nelson and Lindstrom 1999), this would give ganglionic neurons yet another way to alter nicotinic activity to address the needs of the cell.

Expression of 7 AChRs in IMR-32 Cells with No Detectable Function
-BGT–sensitive currents have been reported in IMR-32 cells previously (Gotti et al. 1995). However, because of current rundown and the relative irreversibility of -BGT blockade, these data are difficult to interpret. In the present study, no IMR-32 currents had rapid kinetics like those of an 7-type response (Alkondon et al. 1992; Gopalakrishnan et al. 1995). We have recorded rapidly desensitizing, Nic-activated currents from rat hippocampal neurons that have been attributed to 7 AChRs to validate the efficiency of our application system (unpublished data). Additionally, we failed to inhibit Nic-evoked currents in IMR-32 cells with the reversible selective 7 AChR antagonist, MLA. Thus, the presence of -BGT binding sites measured on the cell surface in IMR-32 cells was perplexing. However, if 7 AChRs have an -BGT binding site for each subunit of a homopentameric AChR, there would be similar numbers of 7 AChRs when compared with 3 AChRs on the cell surface. Considering that the channel closing rate for homomeric 7 AChRs is at least 10,000 s^–1 ([Anand et al. 1998] compared with 150 s^–1 for 3β4 AChRs [Fig. 9]) and its desensitization rate is at least 3000 s^–1 (unpublished data; compared with 2 s^–1 for 3β4 AChRs [Fig. 8]) this number of 7 AChRs might fail to generate measurable current. Consistent with this reasoning, we estimate that there are sevenfold fewer -BGT binding sites in IMR-32 cells than have been reported for transfected HEK cells from which human 7 AChRs have been characterized electrophysiologically (Gopalakrishnan et al. 1995). However, we cannot eliminate the possibility that the 7 AChRs expressed by IMR-32 cells are, indeed, nonfunctional. To test for the presence of nonhomomeric 7 AChRs with unexpected functional properties, we immunoisolated AChRs that contained either 3, 5, or β2 subunits, and then attempted to label them with ¹²⁵I--BGT. No labeling was observed on these AChRs, but 7-selective mAbs 306 and 319 bound 40 ± 4 fmol of ¹²⁵I--BGT from these same extracts confirming the presence of an 7 AChR with high affinity for toxin.

Conclusion
The physiological significance of the potential for such functional diversity among AChRs within individual neurons remains unclear. 7 AChRs are highly permeable to Ca²⁺, which makes them good candidates for triggering Ca²⁺-dependent events to alter expression of proteins involved in morphological or functional changes. The same may also be true of 3β2 AChRs as it has been shown previously that 3β2 AChRs have higher Ca²⁺ permeability than 3β4 AChRs. In fact, the more Ca²⁺-permeable AChRs might mediate development and plasticity, whereas 3β4 AChRs mediate excitatory synaptic transmission. In any case, it is possible that relative amounts of AChR subtypes expressed might vary in neurons from one ganglion to the next. Our data indicate that IMR-32 cells express 3β4 AChRs as the predominant functional AChRs. What remains to be elucidated is what mechanisms are used by ganglionic neurons to alter the proportions of AChR subtypes in response to changing cellular needs. Both incubation in Nic and temperature reduction provide useful models through which to study at least part of these regulatory mechanisms.

Abbreviations used in this paper: AChR, acetylcholine receptor; Cyt, cytisine; HEK, human embryonic kidney; MLA, methyllycaconitine; Nic, nicotine; RIA, radioimmune assay.

	ACKNOWLEDGMENTS

 
The authors thank John Cooper and Ben McNeil for their technical assistance.

This work supported by grants to J. Lindstrom from the National Institutes of Health (NS11323) and the Smokeless Tobacco Research Council, Inc., USA, Inc.

Submitted: 30 April 2001
Revised: 28 September 2001
Accepted: 1 October 2001

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

Alkondon M. & Albuquerque E.X.. Presence of alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat olfactory bulb neurons, Neurosci. Lett., 176, 1994, 152–156.[Medline]

Alkondon M., Pereira E.F., Wonnacott S. & Albuquerque E.X.. Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist, Mol. Pharmacol., 41, 1992, 802–808.[Abstract]

Anand R., Nelson M.E., Gerzanich V., Wells G.B. & Lindstrom J.. Determinants of channel gating located in the N-terminal extracellular domain of nicotinic 7 receptor, J. Pharmacol. Exp. Therap., 287, 1998, 469–479.[Abstract/Free Full Text]

Benowitz N., Porchet H. & Jacob P.. Pharmocokinetics, metabolism, and pharmacodynamics of nicotine, Wonnacott S., Russell M. & Stolerman I., Nicotine Psychophamacology, 1990, 112–157, Oxford Science Publications, Oxford, England.

Betz H., Kuhse J., Schmieden V., Malosio M.L., Langosch D., Prior P., Schmitt B. & Kirsch J.. How to build a glycinergic postsynaptic membrane, J. Cell Sci. Suppl, 15, 1991, 23–25.[Medline]

Bloch R.J. & Froehner S.C.. The relationship of the postsynaptic 43K protein to acetylcholine receptors in receptor clusters isolated from cultured rat myotubes, J. Cell Biol., 104, 1987, 645–654.[Abstract/Free Full Text]

Cooper S.T., Harkness P.C., Baker E.R. & Millar N.S.. Up-regulation of cell-surface 4β2 neuronal nicotinic receptors by lower temperature and expression of chimeric subunits, J. Biol.Chem, 274, 1999, 27145–271452.[Abstract/Free Full Text]

Covernton P.J., Kojima H., Sivilotti L.G., Gibb A.J. & Colquhoun D.. Comparison of neuronal nicotinic receptors in rat sympathetic neurones with subunit pairs expressed in Xenopus oocytes, J. Physiol., 481, 1994, 27–34.[Abstract/Free Full Text]

Franceschini D., Orr-Urtreger A., Yu W., Mackey L.Y., Bond R.A., Armstrong D., Patrick J.W., Beaudet A.L. & De Biasi M.. Altered baroreflex responses in 7 deficient mice, Behav Brain Res, 113, 2000, 3–10.[Medline]

Gerzanich V., Wang F., Kuryatov A. & Lindstrom J.. 5 subunit alters desensitization, pharmacology, Ca²⁺ permeability, and Ca²⁺ modulation of human neuronal 3 nicotinic receptors, J. Pharmacol. Exp. Therap., 286, 1998, 311–320.[Abstract/Free Full Text]

Gopalakrishnan M., Buisson B., Touma E., Giordano T., Campbell J.E., Hu I.C., Donnelly-Roberts D., Arneric S.P., Bertrand D. & Sullivan J.P.. Stable expression and pharmacological properties of the human 7 nicotinic acetylcholine receptor, Eur. J. Pharmacol., 290, 1995, 237–246.[Medline]

Gotti C., Briscini L., Verderio C., Oortgiesen M., Balestra B. & Clementi F.. Native nicotinic acetylcholine receptors in human imr32 neuroblastoma cellsfunctional, immunological and pharmacological properties, Eur. J. Neurosci., 7, 1995, 2083–2092.[Medline]

Gotti C., Fornasari D. & Clementi F.. Human neuronal nicotinc receptors, Prog. Neurobiol., 53, 1997, 199–237.[Medline]

Haghighi A.P. & Cooper E.. Neuronal nicotinic acetylcholine receptors are blocked by intracellular spermine in a voltage-dependent manner, J. Neurosci., 18, 1998, 4050–4062.[Abstract/Free Full Text]

Haghighi A.P. & Cooper E.. A molecular link between inward rectification and calcium permeability of neuronal nicotinic acetylcholine 3β4 and 4β2 receptors, J. Neurosci., 20, 2000, 529–541.[Abstract/Free Full Text]

Hall Z.W. & Sanes J.R.. Synaptic structure and developmentthe neuromuscular junction, Cell., 72Suppl1993, 99–121.[Medline]

Hamill O.P., Marty A., Neher E., Sakmann B. & Sigworth F.J.. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches, Pflügers Arch., 391, 1981, 85–100.[Medline]

Kuryatov A., Olale F.A., Choi C. & Lindstrom J.. Acetylcholine receptor extracellular domain determines sensitivity to nicotine-induced inactivation, Eur. J. Pharmacol., 393, 2000, 11–21.[Medline]

Lane R.D., Crissman R.S. & Ginn S.. High efficiency fusion procedure for producing monoclonal antibodies against weak immunogens, Methods Enzymol., 121, 1986, 183–192.[Medline]

Mandelzys A., Pie B., Deneris E.S. & Cooper E.. The developmental increase in ACh current densities on rat sympathetic neurons correlates with changes in nicotinic ACh receptor -subunit gene expression and occurs independent of innervation, J. Neurosci., 14, 1994, 2357–2364.[Abstract]

McGehee D.S. & Role L.W.. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons, Annu. Rev. Phys., 57, 1995, 521–546.[Medline]

Nelson M.E. & Lindstrom J.. Single channel properties of human 3 AChRsimpact of β2, β4 and 5 subunits, J. Physiol., 516, 1999, 657–678.[Abstract/Free Full Text]

Orr-Urtreger A., Goldner F.M., Saeki M., Lorenzo I., Goldberg L., De Biasi M., Dani J.A., Patrick J.W. & Beaudet A.L.. Mice deficient in the 7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents, J. Neurosci., 17, 1997, 9165–9171.[Abstract/Free Full Text]

Palma E., Bertrand S., Binzoni T. & Bertrand D.. Neuronal nicotinic 7 receptor expressed in Xenopus oocytes presents five putative binding sites for methyllycaconitine, J. Physiol., 491, 1996, 151–161.[Abstract/Free Full Text]

Papke R.L. & Heinemann S.F.. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the β2 subunit, Mol. Pharmacol., 45, 1994, 142–149.[Abstract]

Peng X., Katz M., Gerzanich V., Anand R. & Lindstrom J.. Human 7 acetylcholine receptorcloning of the 7 subunit from the SH-SY5Y cell line and determination of pharmacological properties of native receptors and functional 7 homomers expressed in Xenopus oocytes, Mol. Pharmacol., 45, 1994, 546–554.[Abstract]

Peng X., Gerzanich V., Anand R., Wang F. & Lindstrom J.. Chronic nicotine treatment up-regulates 3 and 7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y, Mol. Pharmacol., 51, 1997, 776–784.[Abstract/Free Full Text]

Ross R.A., Spengler B.A. & Biedler J.L.. Coordinate morphological and biochemical interconversion of human neuroblastoma cells, J. Natl. Cancer Inst., 71, 1983, 741–747.[Medline]

Rust G., Burgunder J.M., Lauterburg T.E. & Cachelin A.B.. Expression of neuronal nicotinic acetylcholine receptor subunit genes in the rat autonomic nervous system, Eur J. Neurosci., 6, 1994, 478–485.[Medline]

Sargent P.B.. The diversity of neuronal nicotinic acetylcholine receptors, Ann. Rev. Neurosci., 16, 1993, 403–443.[Medline]

Tumilowicz J.J., Nichols W.W., Cholon J.J. & Greene A.E.. Definition of a continuous human cell line derived from neuroblastoma, Cancer Res., 30, 1970, 2110–2118.[Abstract/Free Full Text]

Ullian E.M., McIntosh J.M. & Sargent P.B.. Rapid synaptic transmission in the avian ciliary ganglion is mediated by two distinct classes of nicotinic receptors, J. Neurosci., 17, 1997, 7210–7219.[Abstract/Free Full Text]

Wang F., Gerzanich V., Wells G.B., Anand R., Peng X., Keyser K. & Lindstom J.. Assembly of the human neuronal nicotinic receptor 3 subunit with β2, β4, and 5 subunits, J. Biol. Chem., 271, 1996, 17656–17665.[Abstract/Free Full Text]

Wang F., Nelson M.E., Kuryatov A., Olale F., Cooper J., Keyser K. & Lindstrom J.. Chronic nicotine treatment upregulates human 3β2, but not 3β4 AChRs stably transfected in human embryonic kidney cells, J. Biol. Chem., 273, 1998, 28721–28732.[Abstract/Free Full Text]

Wang H., Bedford F.K., Brandon N.J., Moss S.J. & Olsen R.W.. GABA(A)-receptor-associated protein links GABA(A) receptors and the cytoskeleton, Nature., 397, 1999, 69–72.[Medline]

Whiting P.J. & Lindstrom J.M.. Characterization of bovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies, J. Neurosci., 8, 1988, 3395–3404.[Abstract]

Xu W., Gelber S., Orr-Urtreger A., Armstrong D., Lewis R.A., Ou C.N., Patrick J., Role L., De Biasi M. & Beaudet A.L.. Megacystis, mydriasis, and ion channel defect in mice lacking the 3 neuronal nicotinic acetylcholine receptor, Proc. Natl. Acad. Sci. USA., 96, 1999, 5746–5751a.[Abstract/Free Full Text]

Xu W., Orr-Urtreger A., Nigro F., Gelber S., Sutcliffe C.B., Armstrong D., Patrick J.W., Role L.W., Beaudet A.L. & De Biasi M.. Multiorgan autonomic dysfunction in mice lacking the β2 and the β4 subunits of neuronal nicotinic acetylcholine receptors, J. Neurosci., 19, 1999, 9298–9305b.[Abstract/Free Full Text]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Walsh, A. P. Govind, R. Mastro, J. C. Hoda, D. Bertrand, Y. Vallejo, and W. N. Green Up-regulation of Nicotinic Receptors by Nicotine Varies with Receptor Subtype J. Biol. Chem., March 7, 2008; 283(10): 6022 - 6032. [Abstract] [Full Text] [PDF]

				Z. Wang, P. A. Low, J. Jordan, R. Freeman, C. H. Gibbons, C. Schroeder, P. Sandroni, and S. Vernino Autoimmune autonomic ganglionopathy: IgG effects on ganglionic acetylcholine receptor current Neurology, May 29, 2007; 68(22): 1917 - 1921. [Abstract] [Full Text] [PDF]

				P. Tumkosit, A. Kuryatov, J. Luo, and J. Lindstrom beta3 Subunits Promote Expression and Nicotine-Induced Up-Regulation of Human Nicotinic {alpha}6* Nicotinic Acetylcholine Receptors Expressed in Transfected Cell Lines Mol. Pharmacol., October 1, 2006; 70(4): 1358 - 1368. [Abstract] [Full Text] [PDF]

				M. Ohtani, T. Oka, M. Badyuk, Y. Xiao, K. J. Kellar, and J. W. Daly Mouse beta-TC6 Insulinoma Cells: High Expression of Functional {alpha}3beta4 Nicotinic Receptors Mediating Membrane Potential, Intracellular Calcium, and Insulin Release Mol. Pharmacol., March 1, 2006; 69(3): 899 - 907. [Abstract] [Full Text] [PDF]

				A. L. Obaid, M. E. Nelson, J. Lindstrom, and B. M. Salzberg Optical studies of nicotinic acetylcholine receptor subtypes in the guinea-pig enteric nervous system J. Exp. Biol., August 1, 2005; 208(15): 2981 - 3001. [Abstract] [Full Text] [PDF]

				H. Fischer, A. Orr-Urtreger, L. W Role, and S. Huck Selective deletion of the {alpha}5 subunit differentially affects somatic-dendritic versus axonally targeted nicotinic ACh receptors in mouse J. Physiol., February 15, 2005; 563(1): 119 - 137. [Abstract] [Full Text] [PDF]

				K. Wang, J. T. Hackett, M. E. Cox, M. van Hoek, J. M. Lindstrom, and S. J. Parsons Regulation of the Neuronal Nicotinic Acetylcholine Receptor by Src Family Tyrosine Kinases J. Biol. Chem., March 5, 2004; 279(10): 8779 - 8786. [Abstract] [Full Text] [PDF]

				P. M. Lang, R. Burgstahler, W. Sippel, D. Irnich, B. Schlotter-Weigel, and P. Grafe Characterization of Neuronal Nicotinic Acetylcholine Receptors in the Membrane of Unmyelinated Human C-Fiber Axons by In Vitro Studies J Neurophysiol, November 1, 2003; 90(5): 3295 - 3303. [Abstract] [Full Text] [PDF]

				M. Alkondon, E. F.R. Pereira, and E. X. Albuquerque NMDA and AMPA Receptors Contribute to the Nicotinic Cholinergic Excitation of CA1 Interneurons in the Rat Hippocampus J Neurophysiol, September 1, 2003; 90(3): 1613 - 1625. [Abstract] [Full Text] [PDF]

				C. Cohen, O. E. Bergis, F. Galli, A. W. Lochead, S. Jegham, B. Biton, J. Leonardon, P. Avenet, F. Sgard, F. Besnard, et al. SSR591813, a Novel Selective and Partial {alpha}4{beta}2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 407 - 420. [Abstract] [Full Text] [PDF]

				R. W. Fitch, Y. Xiao, K. J. Kellar, and J. W. Daly Membrane potential fluorescence: A rapid and highly sensitive assay for nicotinic receptor channel function PNAS, April 15, 2003; 100(8): 4909 - 4914. [Abstract] [Full Text] [PDF]

				N. Wang, A. Orr-Urtreger, J. Chapman, R. Rabinowitz, and A. D. Korczyn Deficiency of Nicotinic Acetylcholine Receptor beta 4 Subunit Causes Autonomic Cardiac and Intestinal Dysfunction Mol. Pharmacol., March 1, 2003; 63(3): 574 - 580. [Abstract] [Full Text] [PDF]

				M. E. Nelson, A. Kuryatov, C. H. Choi, Y. Zhou, and J. Lindstrom Alternate Stoichiometries of alpha 4beta 2 Nicotinic Acetylcholine Receptors Mol. Pharmacol., February 1, 2003; 63(2): 332 - 341. [Abstract] [Full Text] [PDF]

				R. Rush, A. Kuryatov, M. E. Nelson, and J. Lindstrom First and Second Transmembrane Segments of alpha 3, alpha 4, beta 2, and beta 4 Nicotinic Acetylcholine Receptor Subunits Influence the Efficacy and Potency of Nicotine Mol. Pharmacol., June 1, 2002; 61(6): 1416 - 1422. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF, 432K) PPT slides of all figures Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JGP Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Nelson, M. E. Articles by Lindstrom, J. Search for Related Content PubMed PubMed Citation Articles by Nelson, M. E. Articles by Lindstrom, J. Social Bookmarking                            What's this?